<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332642</url>
  </required_header>
  <id_info>
    <org_study_id>2014-624N-MA</org_study_id>
    <nct_id>NCT02332642</nct_id>
  </id_info>
  <brief_title>Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy</brief_title>
  <acronym>ImmunoPAX</acronym>
  <official_title>Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial aims at evaluating immuno-modulating effects of palliative
      treatment with specifically dosed standard chemotherapeutics in patients with metastatic
      melanoma (AJCC stage IV) by assessing myeloid-derived suppressor cells' (MDSCs) count and
      activity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immuno-monitoring</measure>
    <time_frame>Immediate</time_frame>
  </primary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Immuno-monitoring</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immuno-monitoring</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Metastatic melanoma patients (AJCC stage IV)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically defined metastatic melanoma patients (AJCC stage IV)

          -  aged 18 to 80 years

          -  at least one prior systemic anti-melanoma therapy; if BRAFV600 positive, at least one
             prior BRAFi therapy

        Exclusion Criteria:

          -  therapy-naive patients

          -  any contra-indications for (specific) systemic chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoffer Gebhardt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mannheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jochen Utikal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim, Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dkfz.de/en/dermato_onko/index.php</url>
    <description>Homepage</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Dr. Christoffer Gebhardt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

